Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amoxicillin trihydrate,potassium clavulanate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amoxicillin trihydrate,potassium clavulanate -

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amoxicillin sodium,potassium clavulanate -

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amoxicillin sodium,potassium clavulanate -

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amoxicillin sodium,potassium clavulanate -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - amoxycillin as amoxycillin trihydrate; clavulanic acid as potassium clavulanate - misc. intra mammary - amoxycillin as amoxycillin trihydrate antibiotic active 200.0 mg/sg; clavulanic acid as potassium clavulanate antibiotic active 50.0 mg/sg - antibiotic & related - cattle lactating | bovine - mastitis | subclinical mastitis

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - amoxycillin as amoxycillin trihydrate; clavulanic acid as potassium clavulanate - oral tablet - amoxycillin as amoxycillin trihydrate antibiotic active 200.0 mg/tb; clavulanic acid as potassium clavulanate antibiotic active 50.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - bacterial infection | bacterial skin disease | bordetella bronchiseptica | corynebacteria | dental infection | enteritis | escherichia coli (e. coli) | infections of the urinary tracts | klebsiella spp. | pasteurella spp. | proteus spp. | pyoderma | respiratory cond. - constricted airways | salmonella | soft tissue infections | staphylococci | streptococci | abscesses | airway constriction | amoxycillin sensitive bacteria | anal sacculitis | associated with viral disease | canine cough syndrome | constriction of airways | escherichia coli | gingivitis | gram negative organisms | gram positive organisms | group d streptococcus | including b-lactamase producin | infectious tracheobronchitis | klebsiella spp. | pasterellosis | pasteurellosis | post parturient bacterial infe | post-parturient infections | primary bacterial infection | proteus spp. | pseudomonas aeruginosa | pyoderma | salmonellosis | septicaemia | staphylococcus spp. | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sens

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 28.7 mg/ml equivalent to amoxycillin 25 mg/ml;  ; potassium clavulanate 8.6 mg/ml equivalent to clavulanic acid 6.25 mg/ml (plus 13% overage);  ;   - powder for oral suspension - 125mg,31.25mg/5ml - active: amoxicillin trihydrate 28.7 mg/ml equivalent to amoxycillin 25 mg/ml   potassium clavulanate 8.6 mg/ml equivalent to clavulanic acid 6.25 mg/ml (plus 13% overage)     excipient: aspartame citric acid guar gum hydrated silica lemon flavour 15020598 orange flavour 055301 ap0551 peach-apricot flavour 26f22 purified talc sodium citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 57.4 mg/ml equivalent to amoxycillin 50 mg/ml;  ; potassium clavulanate 17.2 mg/ml equivalent to clavulanic acid 12.5 mg/ml (pius 13% overage);  ;   - powder for oral suspension - 250mg, 62.5mg/5ml - active: amoxicillin trihydrate 57.4 mg/ml equivalent to amoxycillin 50 mg/ml   potassium clavulanate 17.2 mg/ml equivalent to clavulanic acid 12.5 mg/ml (pius 13% overage)     excipient: aspartame citric acid guar gum hydrated silica lemon flavour 15020598 orange flavour 055301 ap0551 peach-apricot flavour 26f22 purified talc sodium citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Australia - English - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - amoxicillin trihydrate, quantity: 1006.25 mg; potassium clavulanate, quantity: 148.875 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; isopropyl alcohol; propylene glycol; dichloromethane; purified talc; ethylcellulose; hypromellose; magnesium stearate; titanium dioxide; hyprolose; industrial methylated spirit - apo-amoxy/clav 500/125 and apo-amoxy/clav 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.